Wednesday Dec 11
Spectrum Pharmaceuticals Highlights Encouraging FOLOTYN and...
'At the ASH meeting there were several presentations on our drugs and we are especially excited about two,' said 'Data from Marqibo's Phase 2 study suggests the drug potentially could have utility in the treatment of Diffuse Large B-cell Lymphoma , in the front-line setting.
John Theurer Cancer Center Presents Genomic Data on Poor Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing at the 55th American Society of Hematology Annual Meeting
Andre Goy, M.D., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates, presented new data providing further insight into the complexity of the genomic landscape in high-risk diffuse large B-cell lymphoma , the most common subtype ... (more)
New Findings from J.A. Silverman and Co-Researchers in the Area of Leukemia Described
In contrast to the rapid CL and wide tissue distribution of non-liposomal VCR, VSLI circulates in plasma for a prolonged period of time, with a slow CL of 345mL/h and relatively small V-d of 3,570mL."
Low-Intensity Chemo Regimen Good Against Burkitt's Lymphoma
A new study demonstrates that adult patients with Burkitt's lymphoma experienced very good long-term survival rates when treated with low-intensity chemotherapy regimens.